Other News To Note
Monday, April 30, 2012
The International Myeloma Foundation, of North Hollywood, Calif., said a new drug application (NDA) has been submitted for pomalidomide, an immunomodulatory agent for multiple myeloma developed by Summit, N.J.-based Celgene Corp. The NDA is seeking use of the drug in patients who no longer respond to other therapies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.